Dr Martin Russell

  • Honorary Clinical Senior Lecturer (Institute of Cancer Sciences)

email: Martin.Russell@glasgow.ac.uk

Cancer Sci & Molecular Pathology, Alexander Stone Building

Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2014 | 2012 | 2006 | 2004
Number of items: 10.

2019

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

2018

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

2017

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

2014

Attard, G. et al. (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. European Urology, 66(5), pp. 799-802. (doi: 10.1016/j.eururo.2014.05.038)

2012

James, N.D. et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, 13(5), pp. 549-558. (doi: 10.1016/S1470-2045(12)70088-8)

Dearnaley, D. et al. (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology, 13(1), pp. 43-54. (doi: 10.1016/S1470-2045(11)70293-5)

2006

Pearson, S., Inglis, S.C., McLennan, S.N., Brennan, L., Russell, M., Wilkinson, D., Thompson, D.R. and Stewart, S. (2006) Prolonged effects of a home-based intervention in patients with chronic illness. Archives of Internal Medicine, 166(6), pp. 645-650.

2004

Russell, M. and Robb, A.J.P. (2004) Career pathways: supporting staff development from intern to consultant. In: 5th European Regional Conference of the Commonwealth Nurses Federation: A Commonwealth of Nations – The Commonwealth for Nurses Across Borders, St Julian's, Malta, 25-27 Mar 2004,

This list was generated on Sun Sep 13 16:47:54 2020 BST.
Number of items: 10.

Articles

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

Attard, G. et al. (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. European Urology, 66(5), pp. 799-802. (doi: 10.1016/j.eururo.2014.05.038)

James, N.D. et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, 13(5), pp. 549-558. (doi: 10.1016/S1470-2045(12)70088-8)

Dearnaley, D. et al. (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology, 13(1), pp. 43-54. (doi: 10.1016/S1470-2045(11)70293-5)

Pearson, S., Inglis, S.C., McLennan, S.N., Brennan, L., Russell, M., Wilkinson, D., Thompson, D.R. and Stewart, S. (2006) Prolonged effects of a home-based intervention in patients with chronic illness. Archives of Internal Medicine, 166(6), pp. 645-650.

Conference Proceedings

Russell, M. and Robb, A.J.P. (2004) Career pathways: supporting staff development from intern to consultant. In: 5th European Regional Conference of the Commonwealth Nurses Federation: A Commonwealth of Nations – The Commonwealth for Nurses Across Borders, St Julian's, Malta, 25-27 Mar 2004,

This list was generated on Sun Sep 13 16:47:54 2020 BST.